US district court holds Aegle Bios liable for willful infringement of Sabinsa’s Tetrahydrocurcuminoid patent

Sabinsa Corp. has again prevailed in legal action protecting one of the company’s patent, this time in a law suit filed against Aegle Bios Inc. (Edison, NJ) for willful patent infringement on June 8, 2016.

On November 7, 2016 the United States District Court for the District of New Jersey, in a written Order, held: “Defendant is liable for willful, induced and contributory infringement, as fully set forth in Plaintiff’s Complaint.” The Court then entered a judgment on liability against Aegle and ordered discovery “to ascertain an accounting of damages, including compensatory, and if any, other enhanced damages.”

“We again call on the industry to respect the Intellectual Property of colleagues and competitors,” said Sabinsa founder Muhammed Majeed, PhD. “We will take any and all legal action required to protect our valuable intellectual property, but encourage other companies not to make that necessary.”

“Sabinsa intends to seek the maximum remedy available under the law for Aegle’s willful infringement, including enhanced damages as identified by the Court” stated James H. Hulme, litigation counsel for Sabinsa.

Sabinsa’s U.S. Patent No. 6,653,327 covers compositional claims and also several topical and oral applications of turmeric-derived tetrahydrocurcuminoids noted for their high anti-oxidant capacity.